- Home
- STC vs BLTE Comparison
STC vs BLTE Comparison
Compare STC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STC
- BLTE
- Stock Information
- Founded
- STC 1893
- BLTE 2018
- Country
- STC United States
- BLTE United States
- Employees
- STC N/A
- BLTE N/A
- Industry
- STC Specialty Insurers
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- STC Finance
- BLTE Health Care
- Exchange
- STC Nasdaq
- BLTE Nasdaq
- Market Cap
- STC 2.0B
- BLTE 1.7B
- IPO Year
- STC N/A
- BLTE 2022
- Fundamental
- Price
- STC $68.95
- BLTE $57.37
- Analyst Decision
- STC Buy
- BLTE Strong Buy
- Analyst Count
- STC 3
- BLTE 4
- Target Price
- STC $77.67
- BLTE $96.33
- AVG Volume (30 Days)
- STC 150.7K
- BLTE 27.8K
- Earning Date
- STC 02-05-2025
- BLTE 03-10-2025
- Dividend Yield
- STC 2.88%
- BLTE N/A
- EPS Growth
- STC 134.79
- BLTE N/A
- EPS
- STC 2.61
- BLTE N/A
- Revenue
- STC $2,488,819,000.00
- BLTE N/A
- Revenue This Year
- STC N/A
- BLTE N/A
- Revenue Next Year
- STC $12.55
- BLTE N/A
- P/E Ratio
- STC $26.62
- BLTE N/A
- Revenue Growth
- STC 10.14
- BLTE N/A
- 52 Week Low
- STC $58.23
- BLTE $31.01
- 52 Week High
- STC $78.44
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- STC 59.79
- BLTE 48.86
- Support Level
- STC $67.41
- BLTE $55.90
- Resistance Level
- STC $68.91
- BLTE $58.54
- Average True Range (ATR)
- STC 1.61
- BLTE 2.70
- MACD
- STC 0.39
- BLTE 0.24
- Stochastic Oscillator
- STC 90.59
- BLTE 52.14
About STC Stewart Information Services Corporation
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.